DeepMatter Group PLC Collaboration with the University of Leeds
17 Junio 2021 - 1:00AM
RNS Non-Regulatory
TIDMDMTR
DeepMatter Group PLC
17 June 2021
17 June 2021
DeepMatter Group Plc
("DeepMatter" or the "Company" or "Group")
DeepMatter collaborates with the Universities of Leeds and
Sheffield
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on
digitising chemistry, has been selected as a partner for the
University of Leeds following a GBP1.4M EPSRC investment they
received to develop automated precision manufacturing approaches in
collaboration with the University of Sheffield, AstraZeneca,
Somaserve and Samsung.
DeepMatter will provide its DigitalGlassware(R) platform, a
cloud-based platform that allow chemists to share data in real-time
and develop digitally enabled scale-up of advanced nanoparticle
products. Nanoparticles are an important component in ensuring safe
and effective drug delivery of new-generation (mRNA) vaccines and
certain anti-cancer drugs. The technology to digitally enable the
scale-up of advanced nanoparticle products will be a sustainable,
cost-effective alternative to the current method of production, and
brings innovation beyond a laboratory setting across several
manufacturing environments.
DigitalGlassware(R) was selected due to its strong fit for
early-stage chemical development. It comprises a cloud-based
software platform, which allows scientists to easily bring together
digitised synthesis protocols (recipes) and contextualises
time-course sensor streams from a range of analytical
instrumentation, importantly in real-time.
In addition to the cloud-based software, DeepMatter will provide
its proprietary low-footprint sensor package, DeviceX, which
provides a new perspective on chemical reaction data, as well as a
hardware device to interface with the continuous platforms at the
University of Leeds. Because of the structuring of content enabled
by DigitalGlassware(R) in the cloud, the aggregated chemical data
is easily amenable to ML and AI applications, from which derived
insights can be applied to shape new experimental design to improve
the outcome of the Grant.
Dr Nicholas Warren, from the School of Chemical and Process
Engineering at the University of Leeds, is leading the research
alongside colleagues Dr Richard Bourne and Dr Thomas Chamberlain
from the School of Chemistry, and researchers from the University
of Sheffield.
Mark Warne, CEO of DeepMatter Group, commented: " We are
delighted to be partnering with both the key opinion leaders at the
University of Leeds and University of Sheffield, as well as large
pharma companies. Our DigitalGlassware(R) platform will be used to
provide a unique perspective on the data helping with both
discovery and productivity gains for chemical reactions forming
nanoparticles - an essential component in delivering effective mRNA
vaccines."
Dr Nicholas Warren, Associate Professor at the University of
Leeds, added: " Sustainable and cost-effective scale-up is yet to
be achieved with nanomaterials production, so to address this issue
we are developing platform technologies with advanced chemical
reactors underpinned by computational intelligence. The data
captured by DigitalGlassware(R) in real-time allows us to use ML
and AI directed decisions contributing to self-optimising reactions
helping us to build up an understanding of the processes and
fine-tune reaction conditions leading to a scaled-up, commercially
viable production of advanced nanoparticle products."
For more information, please contact:
DeepMatter Group plc T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated T: 020 7523 8000
Advisor and Broker)
Bobbie Hilliam
Alma PR T: 020 3405 0205
Caroline Forde / Harriet Jackson / Kieran deepmatter@almapr.co.uk
Breheny / Faye Calow
About DeepMatter Group plc
DeepMatter is building and commercialising the most powerful
data platforms, to enable scientists to easily perform and optimise
chemical reactions, by increasingly integrating chemistry with
technology. Ultimately this will allow the greater use of
artificial intelligence and reaching a point where chemicals can be
autonomously synthesised through robotics.
Visit: www.deepmatter.io and follow @deepmattergroup
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFEESMEFSEEM
(END) Dow Jones Newswires
June 17, 2021 02:00 ET (06:00 GMT)
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024